Table 3.

Multivariate analyses of variables associated with LRR in the entire cohort and in patients with different molecular subtypes of breast cancer.

Variable	P value
	Entire cohort	Luminal HER2-negative	Luminal HER2-positive	HER2- overexpressing	Triple- negative	Unknown subtype
Treatment era 1997–2007 vs. 2008–2014	0.915	0.571	0.774	0.931	0.592	0.133
≤40 vs. >40 years old	0.003	0.096	0.447	0.911	0.839	0.096
Inner quadrants vs. others	<0.001	0.003	0.681	0.530	0.154	0.002
pT1 vs. pT2	<0.001	<0.001	0.384	0.799	0.007	0.064
<10 vs. ≥10 nodes removed	0.084	0.344	0.641	0.864	0.145	0.094
1 vs. 2–3 positive nodes	0.001	0.048	0.082	0.602	0.005	0.054
G1-2 vs. G3	0.002	0.147	0.467	0.094	0.814	0.454
LVI + vs. LVI-	0.147	0.249	0.387	0.044	0.672	0.981
RT vs. no RT	<0.001	<0.001	0.010	0.821	0.001	0.002
Chemotherapy vs. no chemotherapy	0.260	0.474	0.416	0.550	0.967	0.961
Endocrine therapy vs. no endocrine therapy	0.001	0.239	0.957	0.081	–	0.453
Anti-HER2- targeted therapy vs. no targeted therapy	0.992	0.973	0.935	0.515	–	0.993

LRR, locoregional recurrence; LVI, lymphovascular invasion; RT, radiotherapy.